From genomic insights to public health impact: opportunities, challenges, and future directions in personalized disease prevention

Mujahideen Oluwadare Ayinde; Kadiri Khairat Temilola; Amos Dangana; Konstatin Koshechkin; Muqadas Raheem

doi:10.18203/2394-6040.ijcmph20254068

Authors

Mujahideen Oluwadare Ayinde Department of Epidemiology and Evidence Based Medicine, First Moscow State Medical University, Moscow, Russia
Kadiri Khairat Temilola Department of Haematology, University of Abuja Teaching Hospital, Abuja, Nigeria
Amos Dangana National Reference Laboratory, Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria
Konstatin Koshechkin Center for Digital Medicine, First Moscow State Medical University, Russia
Muqadas Raheem Department of Epidemiology and Evidence Based Medicine, First Moscow State Medical University, Moscow, Russia

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20254068

Keywords:

Precision public health, Genomic data integration, Personalized disease prevention, Polygenic risk scores, Artificial intelligence

Abstract

Genomic science is rapidly reshaping healthcare, offering unprecedented opportunities to prevent disease through precision approaches. When combined with traditional public health strategies, genomic data can enable earlier detection, refined risk stratification, and more targeted interventions, a vision often described as precision public health. Despite this promise, real-world integration remains limited. Methodological challenges such as ancestry bias, outcome heterogeneity, and inconsistent study designs undermine generalizability. Technical barriers, including fragmented data systems and poor interoperability, restrict scalability. Ethical concerns around privacy, equity, and governance further complicate implementation, particularly in resource-limited settings. This narrative review synthesizes current applications of genomic public health integration, including polygenic risk scores (PRS), infectious disease surveillance, and digital health initiatives. It highlights key opportunities for enhancing personalized disease prevention while critically examining persistent methodological, technical, and ethical barriers. Future progress will depend on diverse population inclusion, methodological standardization, interoperable infrastructures, and robust ethical frameworks. By addressing these gaps, genomic insights can move from research settings to scalable, equitable public health impact.

Metrics

Metrics Loading ...

References

Roberts MC, Fohner AE, Landry L, Olstad DL, Smit AK, Turbitt E, et al. Advancing precision public health using human genomics: examples from the field and future research opportunities. Genome Med. 2021;13(1):97. DOI: https://doi.org/10.1186/s13073-021-00911-0

Nicholls SG, Etchegary H, Carroll JC, Castle D, Lemyre L, Potter BK, et al. Attitudes to incorporating genomic risk assessments into population screening programs: the importance of purpose, context and deliberation. BMC Med Genomics. 2016;9(1):25. DOI: https://doi.org/10.1186/s12920-016-0186-5

Laviolle B, Denèfle P, Gueyffier F. The contribution of genomics in the medicine of tomorrow, clinical applications and issues. Therapie. 2019;74(1):9-15. DOI: https://doi.org/10.1016/j.therap.2018.11.012

Ioannidis JPA, Khoury MJ. Evidence-based medicine and big genomic data. Hum Mol Genet. 2018;27(R1):R2-7. DOI: https://doi.org/10.1093/hmg/ddy065

Corti C, Cobanaj M, Dee EC, Criscitiello C, Tolaney SM, Celi LA, et al. Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. Cancer Treat Rev. 2023;112:102498. DOI: https://doi.org/10.1016/j.ctrv.2022.102498

Prosperi M, Min JS, Bian J, Modave F. Big data hurdles in precision medicine and precision public health. BMC Med Inform Decis Mak. 2018;18(1):139. DOI: https://doi.org/10.1186/s12911-018-0719-2

Marshall DA, Gonzalez JM, MacDonald K V, Johnson FR. Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. Value Health. 2017;20(1):32-9. DOI: https://doi.org/10.1016/j.jval.2016.08.737

Slavkin HC. From high definition precision healthcare to precision public oral health: opportunities and challenges. J Public Health Dent. 2020;80(1):S23-30. DOI: https://doi.org/10.1111/jphd.12296

Ersek JL, Black LJ, Thompson MA, Kim ES. Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices. Am Soc Clin Oncol Educ Book. 2018;38:188-96. DOI: https://doi.org/10.1200/EDBK_200633

Kee F, Taylor-Robinson D. Scientific challenges for precision public health. J Epidemiol Community Health (1978). 2020;74(4):311-4. DOI: https://doi.org/10.1136/jech-2019-213311

Solis N, Zavaleta E, Wernhoff P, Dominguez-Barrera C, Dominguez-Valentin M. Challenges to Bringing Personalized Medicine to a Low-Resource Setting in Peru. Int J Environ Res Public Health. 2021;18:4. DOI: https://doi.org/10.3390/ijerph18041470

Yang X, Huang K, Yang D, Zhao W, Zhou X. Biomedical Big Data Technologies, Applications, and Challenges for Precision Medicine: A Review. Global Challenges. 2024;8(1):1-21. DOI: https://doi.org/10.1002/gch2.202300163

Connolly JJ, Berner ES, Smith M, Levy S, Terek S, Harr M, et al. Education and electronic medical records and genomics network, challenges, and lessons learned from a large-scale clinical trial using polygenic risk scores. Vol. 25, Genetics in Medicine. Elsevier B.V. 2023. DOI: https://doi.org/10.1016/j.gim.2023.100906

Lewis CM, Vassos E. Polygenic risk scores: From research tools to clinical instruments. Vol. 12, Genome Medicine. BioMed Central Ltd. 2020. DOI: https://doi.org/10.1186/s13073-020-00742-5

Ramos PIP, Marcilio I, Bento AI, Penna GO, de Oliveira JF, Khouri R, et al. Combining Digital and Molecular Approaches Using Health and Alternate Data Sources in a Next-Generation Surveillance System for Anticipating Outbreaks of Pandemic Potential. JMIR Public Health Surveill. 2024;10:e47673. DOI: https://doi.org/10.2196/47673

Aanensen DM, Feil EJ, Holden MTG, Dordel J, Yeats CA, Fedosejev A. Whole-Genome Sequencing for Routine Pathogen Surveillance in Public Health: a Population Snapshot of Invasive Staphylococcus aureus in Europe. 2016;7(3):1-15. DOI: https://doi.org/10.1128/mBio.00444-16

Reitsma M, Fox J, Borre P Vanden, Cavanaugh M, Chudnovsky Y, Erlich RL, et al. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. J Manag Care Spec Pharm. 2019;25(5):601-11. DOI: https://doi.org/10.18553/jmcp.2019.18309

Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(22):2907-21. DOI: https://doi.org/10.2217/fon-2021-0153

Bylstra Y, Lim WK, Kam S, Tham KW, Wu RR, Teo JX, et al. Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Med. 2021;13(1):3. DOI: https://doi.org/10.1186/s13073-020-00819-1

De Paoli P, Ciliberto G, Ferrarini M, Pelicci P, Dellabona P, De Lorenzo F, et al. Alliance Against Cancer, the network of Italian cancer centers bridging research and care. J Transl Med. 2015;13:360. DOI: https://doi.org/10.1186/s12967-015-0711-x

De Lazzari G, Opattova A, Arena S. Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients. J Exp Clin Cancer Res. 2024;43(1):146. DOI: https://doi.org/10.1186/s13046-024-03065-0

Kelly TN, Sun X, He KY, Brown MR, Taliun SAG, Hellwege JN, et al. Insights from a Large-Scale Whole-Genome Sequencing Study of Systolic Blood Pressure, Diastolic Blood Pressure, and Hypertension. Hypertension. 2022;79(8):1656-67. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.122.19324

Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Vol. 53, Nature Genetics. Nature Res. 2021;420-5. DOI: https://doi.org/10.1038/s41588-021-00783-5

Fahed AC, Aragam KG, Hindy G, Chen YDI, Chaudhary K, Dobbyn A, et al. Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease. Circ Genom Precis Med. 2021;14(1):E003092. DOI: https://doi.org/10.1161/CIRCGEN.120.003092

Dini V, Martini P, Bellini M, Bagnoni G, Marsili F, Lancia U. Psoriatic arthritis prevalence in the clinical practice of dermatologists in North-West Tuscany centers of excellence: a screening experience. G Ital Dermatol Venereol. 2017;152(1):24-7. DOI: https://doi.org/10.23736/S0392-0488.16.05232-9

Ochola R. The Case for Genomic Surveillance in Africa. Vol. 10, Tropical Medicine and Infectious Disease. Multidisciplinary Digital Publishing Institute (MDPI). 2025. DOI: https://doi.org/10.3390/tropicalmed10050129

Tokita J, Lam D, Vega A, Wang S, Amoruso L, Muller T, et al. A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease. J Prim Care Community Health. 2024;15:21501319231223436. DOI: https://doi.org/10.1177/21501319231223437

Carey DJ, Fetterolf SN, Davis FD, Faucett WA, Kirchner HL, Mirshahi U, et al. The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet Med. 2016;18(9):906-13. DOI: https://doi.org/10.1038/gim.2015.187

Thomassin-Naggara I, Balleyguier C, Ceugnart L, Heid P, Lenczner G, Maire A, et al. Artificial intelligence and breast screening: French Radiology Community position paper. Diagn Interv Imaging. 2019;100(10):553-66. DOI: https://doi.org/10.1016/j.diii.2019.08.005

Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P, et al. Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine. Epidemiology. 2016;27(4):602-11. DOI: https://doi.org/10.1097/EDE.0000000000000471

Chebly A. Cancer cytogenetics in the era of artificial intelligence: shaping the future of chromosome analysis. Future Oncol. 2024;20(31):2303-5. DOI: https://doi.org/10.1080/14796694.2024.2385296

Najib T, Wasi W, Muntasir F, Ahmed N. Federated Learning in Healthcare: Preserving Privacy, Unleashing Potential. ResearchGate. 2024. DOI: https://doi.org/10.1201/9781003543596-9

Mulder N, Abimiku A, Adebamowo SN, de Vries J, Matimba A, Olowoyo P, et al. H3Africa: Current perspectives. Vol. 11, Pharmacogenomics and Personalized Medicine. Dove Medical Press Ltd. 2018;59-66. DOI: https://doi.org/10.2147/PGPM.S141546

Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590(7845):290-9. DOI: https://doi.org/10.1038/s41586-021-03205-y

Weitzel KW, Alexander M, Bernhardt BA, Calman N, Carey DJ, Cavallari LH, et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics. 2016;9:1. DOI: https://doi.org/10.1186/s12920-015-0162-5

Frampton MJE, Law P, Litchfield K, Morris EJ, Kerr D, Turnbull C, et al. Implications of polygenic risk for personalised colorectal cancer screening. Ann Oncol. 2016;27(3):429-34. DOI: https://doi.org/10.1093/annonc/mdv540

Owen CG, Tai ES, Sun S. Precision Medicine and Big Data: The Application of an Ethics Framework for Big Data in Health and Research. Asian Bioeth Rev. 2019;11(3):275-88. DOI: https://doi.org/10.1007/s41649-019-00094-2

Dunnenberger HM, Biszewski M, Bell GC, Sereika A, May H, Johnson SG, et al. Implementation of a multidisciplinary pharmacogenomics clinic in a community health system. Am J Health Syst Pharm. 2016;73(23):1956-66. DOI: https://doi.org/10.2146/ajhp160072

Menon U, Ashing K, Chang MW, Christy SM, Friberg-Felsted K, Rivas VG, et al. Application of the ConNECT Framework to Precision Health and Health Disparities. Nurs Res. 2019;68(2):99-109. DOI: https://doi.org/10.1097/NNR.0000000000000329